This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Cooper Companies' CEO Presents At JP Morgan Healthcare Conference (Transcript)

The Cooper Companies Inc. ( COO)

JP Morgan Healthcare Conference

January 11, 2012 2:00 PM ET

Executives

Bob Weiss – President and CEO

Analysts

Kim Gailun – JPMorgan

Presentation

Kim Gailun – JPMorgan

Good afternoon. I’m Kim Gailun with the JPMorgan MedTech team. Presenting next, we have The Cooper Companies. And we’re thrilled to have with us today, CEO, Bob Weiss. I just wanted to mention before I turn it over to Bob two items. The first is please turn off all cell phones in the room; and the second is that we will take all questions in the breakout room, which is in the Sussex Room down the hall here to the right. So, Bob?

Bob Weiss

Well, I can tell some of us are on East Coast Time, it’s morning in California, but that’s okay. By the way, my voice has gone a couple times this morning as we had one-on-one meetings. If it does, I’m going to quickly sit down, and Al White will get up and finish my sentence and keep going. So bear with me, but we’ll hope for the best here.

First of all, The Cooper Companies is a New York Stock Exchange company. I’ll let you glance at the forward-looking statements. And obviously anything I say that’s forward looking, it’s covered accordingly. As I indicated, it’s a New York Stock Exchange company. It has revenue of around $1.3 billion. It has two businesses: CooperVision is our contact lens business, soft contact lens business, represents 85% of the overall revenue. The soft contact lens business is approaching $7 billion now, $6.9 billion this year probably. We are the number three player in that market with really four primary players: J&J, VISTAKON, CIBA, Alcon -- part of Novartis, Cooper and Bausch & Lomb.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs